...
search icon
mens-img

JYONG BIOTECH LTD, Common Stock

MENS

NMQ

$7.94

-$1.68

(-17.46%)

1D
Sector: Healthcare

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$603.66M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.01 L
$19.99 H
$7.94

About JYONG BIOTECH LTD, Common Stock

Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer. more

Sector: Healthcare

Returns

Data is not properly formatted.

Financials

Dec '21Dec '22Dec '23Dec '24
Total Revenue----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses2.40M2.83M2.80M2.06M[{"date":"2021-12-31","value":84.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.87,"profit":true},{"date":"2024-12-31","value":72.68,"profit":true}]
Operating Income(2.40M)(2.83M)(2.80M)(2.06M)[{"date":"2021-12-31","value":-240400000,"profit":false},{"date":"2022-12-31","value":-282900000,"profit":false},{"date":"2023-12-31","value":-279700000,"profit":false},{"date":"2024-12-31","value":-205600000,"profit":false}]
Total Non-Operating Income/Expense(2.62M)(4.56M)(2.30M)(1.99M)[{"date":"2021-12-31","value":-262300000,"profit":false},{"date":"2022-12-31","value":-456100000,"profit":false},{"date":"2023-12-31","value":-230400000,"profit":false},{"date":"2024-12-31","value":-199100000,"profit":false}]
Pre-Tax Income(4.20M)(6.63M)(4.40M)(3.02M)[{"date":"2021-12-31","value":-419800000,"profit":false},{"date":"2022-12-31","value":-663000000,"profit":false},{"date":"2023-12-31","value":-440000000,"profit":false},{"date":"2024-12-31","value":-301900000,"profit":false}]
Income Taxes----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(4.20M)(6.63M)(4.40M)(3.02M)[{"date":"2021-12-31","value":-419800000,"profit":false},{"date":"2022-12-31","value":-663000000,"profit":false},{"date":"2023-12-31","value":-440000000,"profit":false},{"date":"2024-12-31","value":-301900000,"profit":false}]
Income From Discontinued Operations----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(4.20M)(6.63M)(4.40M)(3.02M)[{"date":"2021-12-31","value":-419800000,"profit":false},{"date":"2022-12-31","value":-663000000,"profit":false},{"date":"2023-12-31","value":-440000000,"profit":false},{"date":"2024-12-31","value":-301900000,"profit":false}]
EPS (Diluted)----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MENS
Cash Ratio 0.01
Current Ratio 0.02

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MENS
ROA (LTM) -17.59%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MENS
Debt Ratio Lower is generally better. Negative is bad. 6.74
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -5.74

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MENS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.00
EV/R 0.00
EV/Ebitda NM

FAQs

What is JYONG BIOTECH LTD share price today?

JYONG BIOTECH LTD (MENS) share price today is $7.94

Can Indians buy JYONG BIOTECH LTD shares?

Yes, Indians can buy shares of JYONG BIOTECH LTD (MENS) on Vested. To buy JYONG BIOTECH LTD from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MENS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of JYONG BIOTECH LTD be purchased?

Yes, you can purchase fractional shares of JYONG BIOTECH LTD (MENS) via the Vested app. You can start investing in JYONG BIOTECH LTD (MENS) with a minimum investment of $1.

How to invest in JYONG BIOTECH LTD shares from India?

You can invest in shares of JYONG BIOTECH LTD (MENS) via Vested in three simple steps:

  • Click on Sign Up or Invest in MENS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in JYONG BIOTECH LTD shares
What is JYONG BIOTECH LTD 52-week high and low stock price?

The 52-week high price of JYONG BIOTECH LTD (MENS) is $19.99. The 52-week low price of JYONG BIOTECH LTD (MENS) is $6.01.

What is JYONG BIOTECH LTD price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of JYONG BIOTECH LTD (MENS) is 0.00

What is the Market Cap of JYONG BIOTECH LTD?

The market capitalization of JYONG BIOTECH LTD (MENS) is $603.66M

What is JYONG BIOTECH LTD’s stock symbol?

The stock symbol (or ticker) of JYONG BIOTECH LTD is MENS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top